{"protocolSection":{"identificationModule":{"nctId":"NCT05546476","orgStudyIdInfo":{"id":"C3651003"},"secondaryIdInfos":[{"id":"2023-510446-24-00","type":"REGISTRY","domain":"CTIS (EU)"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15","officialTitle":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)","acronym":"PROACC-1"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"COMPLETED","startDateStruct":{"date":"2022-11-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-03-13","type":"ACTUAL"},"completionDateStruct":{"date":"2025-04-23","type":"ACTUAL"},"studyFirstSubmitDate":"2022-08-12","studyFirstSubmitQcDate":"2022-09-15","studyFirstPostDateStruct":{"date":"2022-09-19","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-03-11","resultsFirstSubmitQcDate":"2025-04-23","resultsFirstPostDateStruct":{"date":"2025-04-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-29","lastUpdatePostDateStruct":{"date":"2025-05-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.","detailedDescription":"A 12 week double blind study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.\n\nDuring the initial 12-week treatment period (Part A), a total of 3 doses of ponsegromab or placebo will be administered 4 weeks apart subcutaneously. Each dose contains two injections. Part B is an optional open-label treatment period consisting of ponsegromab administered every 4 weeks subcutaneously for up to one year. Part B does not include placebo.\n\nAssessments include:\n\n* Body weight measurements\n* Measure the impact of ponsegromab compared to placebo on physical activity.\n* Measure the impact of ponsegromab compared to placebo on appetite, fatigue, nausea, vomiting and physical function questionnaires.\n* Blood samples to evaluate safety and additional endpoints including the amount of study drug in the blood and the effects of the study drug on levels of GDF15\n* Up to 3 additional blood samples (two samples during Part A and one sample during Part B, if relevant) in a subset of participants as part of a substudy for more comprehensive assessment of the amount of study drug in the blood and of the effects of the study drug on levels of GDF-15."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer","Pancreatic Cancer","Colorectal Cancer","Loss of Appetite","Fatigue","Cachexia"],"keywords":["cancer","anorexia","cachexia","weight loss","loss of appetite","fatigue"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Double-blind for 12-week double-blind treatment period followed by an up to 1 year optional open-label treatment period","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":187,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab Treatment","type":"EXPERIMENTAL","description":"ponsegromab low dose subcutaneous injection every 4 weeks","interventionNames":["Drug: ponsegromab"]},{"label":"Double-Blind Placebo Treatment followed by Open-Label ponsegromab Treatment","type":"PLACEBO_COMPARATOR","description":"Match placebo subcutaneous injection every 4 weeks","interventionNames":["Drug: Placebo for ponsegromab"]},{"label":"Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab Treatment","type":"EXPERIMENTAL","description":"ponsegromab medium dose subcutaneous injection every 4 weeks","interventionNames":["Drug: ponsegromab"]},{"label":"Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab Treatment","type":"EXPERIMENTAL","description":"ponsegromab high dose subcutaneous injection every 4 weeks","interventionNames":["Drug: ponsegromab"]}],"interventions":[{"type":"DRUG","name":"ponsegromab","description":"Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment","armGroupLabels":["Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab Treatment","Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab Treatment","Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab Treatment"]},{"type":"DRUG","name":"Placebo for ponsegromab","description":"Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment","armGroupLabels":["Double-Blind Placebo Treatment followed by Open-Label ponsegromab Treatment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: Change From Baseline in Body Weight at Week 12","description":"Body weight was measured in kilograms using a calibrated weighing scale. Baseline was defined as the last average of the duplicate measurements prior to, or on Day 1. The average of the duplicate body weights collected at assessment time was considered. The posterior medians and 90 percent (%) credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for each randomized dose (including placebo). 4-Parameter maximal effect (E max) model: change from baseline = E 0 + (E max \\* dose\\^Hill) / (ED 50\\^Hill + dose\\^Hill), where E0 is the placebo effect, E max is the maximum effect, ED 50 is the dose producing 50% of the maximum effect, and Hill is the slope parameter. Model utilized a Bayesian methodology with a robustified, informative meta-analytic predictive prior for the placebo change from baseline at week 12.","timeFrame":"Baseline, Week 12"}],"secondaryOutcomes":[{"measure":"Part A: Change From Baseline in Physical Activity at Week 12","description":"Physical activity was monitored using accelerometry (wearable digital sensors). Physical activity was categorized as: sedentary activity, non-sedentary physical activity, and moderate to vigorous physical activity. In this outcome measure time for each type of physical activity per day was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using mixed models repeated measures (MMRM) model.","timeFrame":"Baseline, Week 12"},{"measure":"Part A: Change From Baseline in Mean Activity Level During Maximum 6 Minutes at Week 12","description":"Physical activity was monitored using accelerometry (wearable digital sensors). In this outcome measure mean activity level during maximum 6 minutes was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","timeFrame":"Baseline, Week 12"},{"measure":"Part A: Change From Baseline in Total Vector Magnitude at Week 12","description":"Total vector magnitude is a measure of overall physical activity. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","timeFrame":"Baseline, Week 12"},{"measure":"Part A: Change From Baseline in Gait at Week 12","description":"Gait was monitored using accelerometry (wearable digital sensors). Analysis was performed using MMRM model. Gait included: gait speed and 95th percentile of gait speed. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","timeFrame":"Baseline, Week 12"},{"measure":"Part A: Change From Baseline in Functional Assessment of Anorexia-Cachexia Therapy- Anorexia and Cachexia Subscale (FAACT-ACS) at Week 12","description":"FAACT-ACS is a 12-item symptom-specific subscale to measure participants' concerns about their anorexia (appetite) or cachexia (weight) for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-ACS score ranged from 0 to 48. Higher scores are associated with a higher health-related quality of life. FAACT-ACS was analyzed using an MMRM model.","timeFrame":"Baseline (prior to dose on Day 1), Week 12"},{"measure":"Part A: Change From Baseline in FAACT- 5-Item Anorexia Symptom Scale (5IASS) at Week 12","description":"FAACT-5IASS is a 5-item subscale to measure participants' perceptions of anorexia (appetite) concerns for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-5IASS score ranged from 0 to 20. Higher scores are associated with a higher health-related quality of life. FAACT-5IASS was analyzed using an MMRM model.","timeFrame":"Baseline (prior to dose on Day 1), Week 12"},{"measure":"Part A: Change From Baseline in Cancer-Related Cachexia Symptom Diary (CRCSD) Scores at Week 12: Appetite, Nausea and Physical Fatigue","description":"The CRCSD is a daily, self-reported questionnaire that measured severity of symptoms related to cancer cachexia: appetite, nausea, vomiting, and fatigue. Participants rated appetite, nausea and physical fatigue symptom every day, and weekly averages were calculated over the 7 days prior, from 0 to 10, where 0 = no symptom and 10 = worst possible symptom. Higher scores indicated more severe disease. CRCSD was analyzed using an MMRM model.","timeFrame":"Baseline, Week 12"},{"measure":"Part A: Median Change From Baseline in CRCSD Scores at Week 12: Vomiting Frequency","description":"The CRCSD is a daily, self-reported questionnaire that measured severity of symptoms related to cancer cachexia: vomiting frequency. Participants rated vomiting frequency over the past 24 hours, from 0 to 30, where 0 = no symptom and 30 = worst possible symptom. Higher scores indicated more severe disease.","timeFrame":"Baseline, Week 12"},{"measure":"Part A: Number of Participants With Treatment Emergent Adverse Events (TEAE)","description":"An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. TEAE were defined as any event that was not present before exposure to study drug, or any event already present that worsened in either intensity or frequency after exposure to study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included serious AEs and all non-SAEs.","timeFrame":"From start of study drug on Day 1 maximum up to 4 weeks post last dose on Week 12 (maximum up to approximately Week 16)"},{"measure":"Part A: Number of Participants With Incidence of Laboratory Test Abnormalities","description":"Laboratory test abnormality parameters included: hematology- hemoglobin (gram per deciliter \\[g/dL\\]), hematocrit (%), erythrocytes (10\\^12/Liter \\[L\\]) less than (\\<) 0.8\\*lower limit of normal (LLN); platelets (10\\^9/L) \\<0.5\\*LLN to more than (\\>) 1.75\\*upper limit of normal (ULN); leukocytes (10\\^9/L) \\<0.6\\*LLN to \\>1.5\\*ULN; lymphocytes, neutrophils (10\\^9/L) \\<0.8\\*LLN to \\>1.2\\*ULN. Clinical chemistry- bilirubin, glucose (mg/dL) \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase (Units/L \\[U/L\\]) \\>3.0\\*ULN; protein, albumin (gram \\[g\\]/dL) \\<0.8\\*LLN; urea (mmol/L) \\>1.3xULN; creatinine (mg/dL) \\>1.3\\*ULN; sodium (milliequivalents \\[mEq\\]/L) \\<0.95\\*LLN; potassium (mEq/L) \\<0.9\\*LLN to \\>1.1\\*ULN.","timeFrame":"Day 1 up to Week 12"},{"measure":"Part A: Number of Participants With Post-Baseline Vital Signs Meeting the Predefined Criteria","description":"Vital signs criteria included: supine systolic blood pressure (SBP) \\<90 millimeters of mercury (mmHg), increase and decrease in change of more than or equal to (\\>=) 30mmHg; supine diastolic blood pressure (DBP) \\<50 mmHg, increase and decrease in change of \\>= 20mmHg; pulse rate \\<40 beats per minute (bpm) to \\>120 bpm. Only rows which included at least 1 participant in any reporting group with abnormality were reported in this outcome measure.","timeFrame":"Day 1 up to Week 12"},{"measure":"Part A: Number of Participants With Clinically Significant Echocardiogram (ECG) Abnormalities","description":"ECG parameters included heart rate (HR), PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF) and QRS complex. HR: RR (interval between 2 successive R waves on ECG) decrease \\>25% and to a VR (interval between QRS wave and T wave on ECG) \\>100, RR increase \\>25% and to a VR \\<50; PR interval: baseline less than or equal to (\\<=) 200 and % change \\>= 50%; QT interval: \\>450, \\>480, \\>500, increase from baseline \\>30, increase from baseline \\>60; QTcF: 470 \\< value \\<= 480, 480 \\< value \\<= 500, value \\> 500, 30 \\< change \\<= 60 and change \\>60; QRS complex: value \\>= 140, % change \\>=50%. Clinically significant values were determined by the investigator.","timeFrame":"Day 1 up to Week 12"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Documented active diagnosis of non-small cell lung, pancreatic, colorectal cancer\n* Cachexia defined by Fearon criteria of weight loss\n* Serum GDF-15 concentrations\n* Signed informed consent\n* ECOG PS ≤3 with life expectancy of at least 4 months to be able to complete Part A.\n\nKey Exclusion Criteria:\n\n* Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.\n* Current active reversible causes of decreased food intake.\n* Cachexia caused by other reasons.\n* History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody.\n* inadequate liver function\n* renal disease requiring dialysis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"CARTI Conway","city":"Conway","state":"Arkansas","zip":"72034","country":"United States","geoPoint":{"lat":35.0887,"lon":-92.4421}},{"facility":"CARTI Cancer Center","city":"Little Rock","state":"Arkansas","zip":"72205","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"CARTI North Little Rock","city":"North Little Rock","state":"Arkansas","zip":"72117","country":"United States","geoPoint":{"lat":34.76954,"lon":-92.26709}},{"facility":"CARTI Stuttgart","city":"Stuttgart","state":"Arkansas","zip":"72160","country":"United States","geoPoint":{"lat":34.50037,"lon":-91.55263}},{"facility":"Pacific Cancer Medical Center INC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Beverly Hills Cancer Center","city":"Beverly Hills","state":"California","zip":"90211","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"facility":"Emad Ibrahim,MD,INC.","city":"Redlands","state":"California","zip":"92373","country":"United States","geoPoint":{"lat":34.05557,"lon":-117.18254}},{"facility":"Providence Medical Foundation","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"IU Health Arnett Cancer Center","city":"Lafayette","state":"Indiana","zip":"47904","country":"United States","geoPoint":{"lat":40.4167,"lon":-86.87529}},{"facility":"Pennington Biomedical Research Center","city":"Baton Rouge","state":"Louisiana","zip":"70808","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Tandem Clinical Research","city":"Marrero","state":"Louisiana","zip":"70072","country":"United States","geoPoint":{"lat":29.89937,"lon":-90.10035}},{"facility":"Bozeman Health Deaconess Hospital","city":"Bozeman","state":"Montana","zip":"59715","country":"United States","geoPoint":{"lat":45.67965,"lon":-111.03856}},{"facility":"Oregon Health and Science University: Center for Health and Healing 1","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Oregon Health and Science University: Center for Health and Healing 2","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Oregon Health and Science University","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"The University of Texas MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Carta - Clinical Associates in Research Therapeutics of America, LLC","city":"San Antonio","state":"Texas","zip":"78212","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Virginia Mason Medical Center","city":"Seattle","state":"Washington","zip":"98101","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Wenatchee Valley Hospital","city":"Wenatchee","state":"Washington","zip":"98801","country":"United States","geoPoint":{"lat":47.42346,"lon":-120.31035}},{"facility":"St Vincent's Hospital Sydney","city":"Darlinghurst","state":"New South Wales","zip":"2010","country":"Australia","geoPoint":{"lat":-33.87939,"lon":151.21925}},{"facility":"Orange Hospital","city":"Orange","state":"New South Wales","zip":"2800","country":"Australia","geoPoint":{"lat":-33.28397,"lon":149.10018}},{"facility":"Peter MacCallum Cancer Centre","city":"Melbourne","state":"Victoria","zip":"3000","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Western Health-Sunshine & Footscray Hospitals","city":"St Albans","state":"Victoria","zip":"3021","country":"Australia","geoPoint":{"lat":-37.74496,"lon":144.80049}},{"facility":"Complex Oncology Center - Burgas","city":"Burgas","zip":"8000","country":"Bulgaria","geoPoint":{"lat":42.50651,"lon":27.46886}},{"facility":"Specialized Hospital for Active Treatment of Oncology - Haskovo","city":"Haskovo","zip":"6300","country":"Bulgaria","geoPoint":{"lat":41.93415,"lon":25.55557}},{"facility":"Complex Oncology Center - Ruse EOOD","city":"Rousse","zip":"7002","country":"Bulgaria","geoPoint":{"lat":43.84872,"lon":25.9534}},{"facility":"Complex Oncology Center - Shumen","city":"Shumen","zip":"9700","country":"Bulgaria","geoPoint":{"lat":43.27064,"lon":26.92286}},{"facility":"Multiprofile Hospital for Active Treatment Serdika EOOD","city":"Sofia","zip":"1303","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"MHAT for Women's Health Nadezhda","city":"Sofia","zip":"1330","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"University Multiprofile Hospital for Active Treatment Sofiamed","city":"Sofia","zip":"1797","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Complex Oncology Center - Vratsa","city":"Vratsa","zip":"3000","country":"Bulgaria","geoPoint":{"lat":43.21052,"lon":23.56312}},{"facility":"The Ottawa Hospital - General Campus","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"CIUSSS- saguenay-Lac-Saint-Jean","city":"Chicoutimi","state":"Quebec","zip":"G7H 5H6","country":"Canada","geoPoint":{"lat":48.41963,"lon":-71.06369}},{"facility":"Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski","city":"Rimouski","state":"Quebec","zip":"G5L 5T1","country":"Canada","geoPoint":{"lat":48.44879,"lon":-68.52396}},{"facility":"Peking University First Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100034","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Henan Cancer Hospital","city":"Zhengzhou","state":"Henan","zip":"450008","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology","city":"Wuhan","state":"Hubei","zip":"430030","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Changzhou No.2 People's Hospital","city":"Changzhou","state":"Jiangsu","zip":"213003","country":"China","geoPoint":{"lat":31.77359,"lon":119.95401}},{"facility":"The First Affiliated Hospital of Nanchang University","city":"Nanchang","state":"Jiangxi","zip":"330006","country":"China","geoPoint":{"lat":28.68396,"lon":115.85306}},{"facility":"Qilu Hospital of Shandong University","city":"Jinan","state":"Shandong","zip":"250012","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Shanghai Changhai Hospital","city":"Shanghai","state":"Shanghai Municipality","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Shanxi Provincial Cancer Hospital","city":"Taiyuan","state":"Shanxi","zip":"030013","country":"China","geoPoint":{"lat":37.86944,"lon":112.56028}},{"facility":"Sir Run Run Shaw Hospital of Zhejiang University School of Medicine","city":"Hangzhou","state":"Zhejiang","zip":"310016","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University","city":"Wenzhou","state":"Zhejiang","zip":"325035","country":"China","geoPoint":{"lat":27.99942,"lon":120.66682}},{"facility":"Bacs-Kiskun Varmegyei Oktatokorhaz","city":"Kecskemét","state":"Bács-Kiskun county","zip":"6000","country":"Hungary","geoPoint":{"lat":46.90618,"lon":19.69128}},{"facility":"Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház","city":"Szolnok","state":"Jász-Nagykun-Szolnok","zip":"5004","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Semmelweis Egyetem","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Országos Korányi Pulmonológiai Intézet","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"National Cancer Center Hospital East","city":"Kashiwa","state":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"facility":"National Hospital Organization Shikoku Cancer Center","city":"Matsuyama","state":"Ehime","zip":"791-0280","country":"Japan","geoPoint":{"lat":33.83916,"lon":132.76574}},{"facility":"Hyogo Cancer Center","city":"Akashi","state":"Hyōgo","zip":"673-8558","country":"Japan","geoPoint":{"lat":34.65524,"lon":135.00687}},{"facility":"Kanagawa cancer center","city":"Yokohama","state":"Kanagawa","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Aichi Cancer Center Hospital","city":"Nagoya","state":"Nagoya, Aichi","zip":"464-8681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Shizuoka Cancer Center","city":"Nagaizumi-cho","state":"Shizuoka","zip":"411-8777","country":"Japan"},{"facility":"University Hospital,Kyoto Prefectural University of Medicine","city":"Kyoto","zip":"602-8566","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"The Cancer Institute Hospital of JFCR","city":"Tokyo","zip":"135-8550","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.","city":"Krakow","state":"Lesser Poland Voivodeship","zip":"30-348","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Regionalny Szpital Specjalistyczny im. Dr. Wladyslawa Bieganskiego","city":"Grudziądz","zip":"86-300","country":"Poland","geoPoint":{"lat":53.48411,"lon":18.75366}},{"facility":"NZOZ \"Vegamed\"","city":"Katowice","zip":"40-060","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"Specjalistyczna Praktyka Lekarska Slawomir Mandziuk","city":"Lublin","zip":"20-093","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica","city":"Banská Bystrica","zip":"975 17","country":"Slovakia","geoPoint":{"lat":48.73947,"lon":19.14932}},{"facility":"Univerzitna nemocnica Bratislava, Nemocnica Ruzinov","city":"Bratislava","zip":"826 06","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Narodny onkologicky ustav, II. Onkologicka klinika LFUK a NOU","city":"Bratislava","zip":"833 10","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Fakultna nemocnica s poliklinikou Nove Zamky","city":"Nové Zámky","zip":"940 34","country":"Slovakia","geoPoint":{"lat":47.98544,"lon":18.16195}},{"facility":"Nemocnica na okraji mesta, n.o.","city":"Partizánske","zip":"95801","country":"Slovakia","geoPoint":{"lat":48.62861,"lon":18.38455}},{"facility":"Fakultna nemocnica Trnava","city":"Trnava","zip":"917 75","country":"Slovakia","geoPoint":{"lat":48.37773,"lon":17.58603}},{"facility":"Hospital Universitari General de Catalunya","city":"Sant Cugat del Vallès","state":"Barcelona [barcelona]","zip":"08915","country":"Spain","geoPoint":{"lat":41.47063,"lon":2.08611}},{"facility":"Institut Català d'Oncologia - L'Hospitalet","city":"L'Hospitalet de Llobregat","state":"Catalunya [cataluña]","zip":"08908","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Hospital Son Llàtzer","city":"Palma","state":"Illes Balears [islas Baleares]","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Fundación Instituto Valenciano de Oncología","city":"Valencia","state":"Valenciana, Comunitat","zip":"46009","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Universitario HM Sanchinarro","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitari i Politecnic La Fe","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Chi Mei Hospital - Liouying Branch","city":"Tainan","state":"Tainan","zip":"73657","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Kaohsiung Medical University Chung-Ho Memorial Hospital","city":"Kaohsiung City","zip":"80756","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"China Medical University Hospital","city":"Taichung","zip":"404332","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"National Cheng Kung University Hospital","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Chang Gung Medical Foundation-Linkou Branch","city":"Taoyuan District","zip":"333","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}}]},"referencesModule":{"references":[{"pmid":"39282907","type":"DERIVED","citation":"Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14."},{"pmid":"38500292","type":"DERIVED","citation":"Groarke JD, Crawford J, Collins SM, Lubaczewski SL, Breen DM, Harrington MA, Jacobs I, Qiu R, Revkin J, Rossulek MI, Saxena AR. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1054-1061. doi: 10.1002/jcsm.13435. Epub 2024 Mar 18."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C3651003"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"A total of 187 participants were enrolled in this study. This study had 2 parts: Part A and Part B. On completion of Part A, participants had the opportunity to enter open-label extension period Part B (optional). Results are reported on the primary completion date of the study. At this milestone Part A analysis (primary and secondary outcome measures) was final.","groups":[{"id":"FG000","title":"Part A: Placebo/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab subcutaneously (SC) once in every 4 weeks (Q4W) up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."},{"id":"FG001","title":"Part A: Ponsegromab 100 mg/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 milligrams (mg) SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."},{"id":"FG002","title":"Part A: Ponsegromab 200 mg/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."},{"id":"FG003","title":"Part A: Ponsegromab 400 mg/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."}],"periods":[{"title":"Period 1: Part A","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"46"},{"groupId":"FG002","numSubjects":"46"},{"groupId":"FG003","numSubjects":"50"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"32"},{"groupId":"FG002","numSubjects":"39"},{"groupId":"FG003","numSubjects":"34"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"16"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Global deterioration of health status","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"4"}]},{"type":"Other: Unspecified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Period 2: Part B","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"29"}]}],"dropWithdraws":[{"type":"Ongoing","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"29"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.","groups":[{"id":"BG000","title":"Part A: Placebo/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."},{"id":"BG001","title":"Part A: Ponsegromab 100 mg/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."},{"id":"BG002","title":"Part A: Ponsegromab 200 mg/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."},{"id":"BG003","title":"Part A: Ponsegromab 400 mg/ Part B: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"187"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.2","spread":"11.26"},{"groupId":"BG001","value":"70.1","spread":"9.38"},{"groupId":"BG002","value":"65.9","spread":"9.61"},{"groupId":"BG003","value":"66.1","spread":"9.93"},{"groupId":"BG004","value":"66.4","spread":"10.28"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"69"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"118"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"9"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"172"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"70"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"35"},{"groupId":"BG004","value":"116"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Change From Baseline in Body Weight at Week 12","description":"Body weight was measured in kilograms using a calibrated weighing scale. Baseline was defined as the last average of the duplicate measurements prior to, or on Day 1. The average of the duplicate body weights collected at assessment time was considered. The posterior medians and 90 percent (%) credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for each randomized dose (including placebo). 4-Parameter maximal effect (E max) model: change from baseline = E 0 + (E max \\* dose\\^Hill) / (ED 50\\^Hill + dose\\^Hill), where E0 is the placebo effect, E max is the maximum effect, ED 50 is the dose producing 50% of the maximum effect, and Hill is the slope parameter. Model utilized a Bayesian methodology with a robustified, informative meta-analytic predictive prior for the placebo change from baseline at week 12.","populationDescription":"Censored analysis set included all evaluable participants. For participants who discontinued study intervention, or received a prohibited procedure or prohibited medication, all observations post-discontinuation, or post-procedure, were censored and treated as missing data. For participants who missed a dose, or received an incomplete dose, all observations post-missed/incomplete dose were censored and treated as missing data.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Kilogram","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"50"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Measure Type = Posterior Median = -0.60 Measure of Dispersion = 90% Credible Interval = -1.50 to 0.24"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Measure Type = Posterior Median = 0.75 Measure of Dispersion = 90% Credible Interval = 0.06 to 1.44"},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Measure Type = Posterior Median = 1.48 Measure of Dispersion = 90% Credible Interval = 0.87 to 2.08"},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Measure Type = Posterior Median = 2.39 Measure of Dispersion = 90% Credible Interval = 1.49 to 3.34"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Bayesian Emax model was used for statistical calculation. The posterior medians and 90% credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for differences relative to placebo). No adjustments were made for multiplicity.","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Posterior Median","paramValue":"1.33","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"2.34"},{"groupIds":["OG000","OG002"],"groupDescription":"Bayesian Emax model was used for statistical calculation. The posterior medians and 90% credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for differences relative to placebo). No adjustments were made for multiplicity.","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Posterior Median","paramValue":"2.08","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.08","ciUpperLimit":"3.15"},{"groupIds":["OG000","OG003"],"groupDescription":"Bayesian Emax model was used for statistical calculation. The posterior medians and 90% credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for differences relative to placebo). No adjustments were made for multiplicity.","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Posterior Median","paramValue":"3","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.68","ciUpperLimit":"4.34"}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in Physical Activity at Week 12","description":"Physical activity was monitored using accelerometry (wearable digital sensors). Physical activity was categorized as: sedentary activity, non-sedentary physical activity, and moderate to vigorous physical activity. In this outcome measure time for each type of physical activity per day was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using mixed models repeated measures (MMRM) model.","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Minutes per day","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}]}],"classes":[{"title":"Time for Sedentary Activity","categories":[{"measurements":[{"groupId":"OG000","value":"-1.42","lowerLimit":"-72.77","upperLimit":"69.92"},{"groupId":"OG001","value":"51.93","lowerLimit":"-9.88","upperLimit":"113.75"},{"groupId":"OG002","value":"-39.33","lowerLimit":"-101.94","upperLimit":"23.29"},{"groupId":"OG003","value":"-3.37","lowerLimit":"-72.89","upperLimit":"66.14"}]}]},{"title":"Time for Non-Sedentary Physical Activity","categories":[{"measurements":[{"groupId":"OG000","value":"-37.73","lowerLimit":"-66.14","upperLimit":"-9.32"},{"groupId":"OG001","value":"0.03","lowerLimit":"-24.88","upperLimit":"24.95"},{"groupId":"OG002","value":"-42.09","lowerLimit":"-67.63","upperLimit":"-16.56"},{"groupId":"OG003","value":"12.11","lowerLimit":"-14.87","upperLimit":"39.10"}]}]},{"title":"Time for Moderate to Vigorous Physical Activity","categories":[{"measurements":[{"groupId":"OG000","value":"-4.45","lowerLimit":"-13.91","upperLimit":"5.02"},{"groupId":"OG001","value":"4.07","lowerLimit":"-4.18","upperLimit":"12.32"},{"groupId":"OG002","value":"0.05","lowerLimit":"-8.29","upperLimit":"8.39"},{"groupId":"OG003","value":"3.67","lowerLimit":"-5.37","upperLimit":"12.71"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.8260","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"53.36","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-40.89","ciUpperLimit":"147.60"},{"groupIds":["OG000","OG002"],"groupDescription":"Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.2540","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-37.9","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-132.94","ciUpperLimit":"57.14"},{"groupIds":["OG000","OG003"],"groupDescription":"Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.4870","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-1.95","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-101.63","ciUpperLimit":"97.73"},{"groupIds":["OG000","OG001"],"groupDescription":"Non-Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0497","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"37.76","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.07","ciUpperLimit":"75.46"},{"groupIds":["OG000","OG002"],"groupDescription":"Non-Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.5745","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-4.36","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-42.94","ciUpperLimit":"34.22"},{"groupIds":["OG000","OG003"],"groupDescription":"Non-Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0189","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"49.85","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"10.62","ciUpperLimit":"89.08"},{"groupIds":["OG000","OG001"],"groupDescription":"Moderate to Vigorous Physical Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.1302","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"8.51","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.00","ciUpperLimit":"21.03"},{"groupIds":["OG000","OG002"],"groupDescription":"Moderate to Vigorous Physical Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.2780","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"4.49","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.18","ciUpperLimit":"17.16"},{"groupIds":["OG000","OG003"],"groupDescription":"Moderate to Vigorous Physical Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.1529","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"8.11","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.01","ciUpperLimit":"21.23"}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in Mean Activity Level During Maximum 6 Minutes at Week 12","description":"Physical activity was monitored using accelerometry (wearable digital sensors). In this outcome measure mean activity level during maximum 6 minutes was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Arbitrary units per day (au/day)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.81","lowerLimit":"-785.82","upperLimit":"927.45"},{"groupId":"OG001","value":"-59.46","lowerLimit":"-794.41","upperLimit":"675.49"},{"groupId":"OG002","value":"794.96","lowerLimit":"39.43","upperLimit":"1550.48"},{"groupId":"OG003","value":"256.43","lowerLimit":"-561.29","upperLimit":"1074.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.5762","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-130.27","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1257.31","ciUpperLimit":"996.77"},{"groupIds":["OG000","OG002"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.1486","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"724.14","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-425.81","ciUpperLimit":"1874.09"},{"groupIds":["OG000","OG003"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.3972","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"185.62","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-997.94","ciUpperLimit":"1369.18"}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in Total Vector Magnitude at Week 12","description":"Total vector magnitude is a measure of overall physical activity. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","populationDescription":"Censored analysis set: all evaluable participants. For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed''=participants evaluable for this outcome measure at Week 12","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Total activity counts/100 per day","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1919.02","lowerLimit":"-3450.37","upperLimit":"-387.68"},{"groupId":"OG001","value":"-331.76","lowerLimit":"-1679.81","upperLimit":"1016.29"},{"groupId":"OG002","value":"-2017.57","lowerLimit":"-3387.48","upperLimit":"-647.65"},{"groupId":"OG003","value":"284.15","lowerLimit":"-1175.46","upperLimit":"1743.77"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0985","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"1587.26","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-443.79","ciUpperLimit":"3618.31"},{"groupIds":["OG000","OG002"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.5315","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-98.54","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2169.67","ciUpperLimit":"1972.58"},{"groupIds":["OG000","OG003"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0437","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"2203.18","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"84.51","ciUpperLimit":"4321.85"}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in Gait at Week 12","description":"Gait was monitored using accelerometry (wearable digital sensors). Analysis was performed using MMRM model. Gait included: gait speed and 95th percentile of gait speed. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Meter per second (m/s)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"14"}]}],"classes":[{"title":"Gait Speed","categories":[{"measurements":[{"groupId":"OG000","value":"-0.008","lowerLimit":"-0.042","upperLimit":"0.026"},{"groupId":"OG001","value":"-0.009","lowerLimit":"-0.040","upperLimit":"0.023"},{"groupId":"OG002","value":"-0.012","lowerLimit":"-0.044","upperLimit":"0.019"},{"groupId":"OG003","value":"0.009","lowerLimit":"-0.024","upperLimit":"0.042"}]}]},{"title":"95th percentile of gait speed","categories":[{"measurements":[{"groupId":"OG000","value":"0.011","lowerLimit":"-0.041","upperLimit":"0.064"},{"groupId":"OG001","value":"0.011","lowerLimit":"-0.037","upperLimit":"0.059"},{"groupId":"OG002","value":"-0.015","lowerLimit":"-0.063","upperLimit":"0.033"},{"groupId":"OG003","value":"0.021","lowerLimit":"-0.030","upperLimit":"0.072"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.5052","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.046","ciUpperLimit":"0.045"},{"groupIds":["OG000","OG002"],"groupDescription":"Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.5599","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-0.004","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.050","ciUpperLimit":"0.042"},{"groupIds":["OG000","OG003"],"groupDescription":"Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.2770","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.017","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.030","ciUpperLimit":"0.064"},{"groupIds":["OG000","OG001"],"groupDescription":"95th Percentile of Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.5047","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.071","ciUpperLimit":"0.070"},{"groupIds":["OG000","OG002"],"groupDescription":"95th Percentile of Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.7316","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-0.026","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.097","ciUpperLimit":"0.045"},{"groupIds":["OG000","OG003"],"groupDescription":"95th Percentile of Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.4145","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.01","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.063","ciUpperLimit":"0.082"}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in Functional Assessment of Anorexia-Cachexia Therapy- Anorexia and Cachexia Subscale (FAACT-ACS) at Week 12","description":"FAACT-ACS is a 12-item symptom-specific subscale to measure participants' concerns about their anorexia (appetite) or cachexia (weight) for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-ACS score ranged from 0 to 48. Higher scores are associated with a higher health-related quality of life. FAACT-ACS was analyzed using an MMRM model.","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline (prior to dose on Day 1), Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","lowerLimit":"-1.60","upperLimit":"2.63"},{"groupId":"OG001","value":"4.76","lowerLimit":"2.54","upperLimit":"6.97"},{"groupId":"OG002","value":"1.15","lowerLimit":"-0.90","upperLimit":"3.20"},{"groupId":"OG003","value":"4.63","lowerLimit":"2.40","upperLimit":"6.85"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0114","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"4.24","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.19","ciUpperLimit":"7.28"},{"groupIds":["OG000","OG002"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.3600","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.64","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.30","ciUpperLimit":"3.57"},{"groupIds":["OG000","OG003"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0138","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"4.11","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.06","ciUpperLimit":"7.17"}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in FAACT- 5-Item Anorexia Symptom Scale (5IASS) at Week 12","description":"FAACT-5IASS is a 5-item subscale to measure participants' perceptions of anorexia (appetite) concerns for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-5IASS score ranged from 0 to 20. Higher scores are associated with a higher health-related quality of life. FAACT-5IASS was analyzed using an MMRM model.","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline (prior to dose on Day 1), Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","lowerLimit":"-0.97","upperLimit":"1.27"},{"groupId":"OG001","value":"2.50","lowerLimit":"1.32","upperLimit":"3.67"},{"groupId":"OG002","value":"0.15","lowerLimit":"-0.94","upperLimit":"1.24"},{"groupId":"OG003","value":"2.45","lowerLimit":"1.28","upperLimit":"3.62"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0090","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"2.35","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"3.97"},{"groupIds":["OG000","OG002"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.4987","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.55","ciUpperLimit":"1.56"},{"groupIds":["OG000","OG003"],"groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0100","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"2.3","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"3.92"}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in Cancer-Related Cachexia Symptom Diary (CRCSD) Scores at Week 12: Appetite, Nausea and Physical Fatigue","description":"The CRCSD is a daily, self-reported questionnaire that measured severity of symptoms related to cancer cachexia: appetite, nausea, vomiting, and fatigue. Participants rated appetite, nausea and physical fatigue symptom every day, and weekly averages were calculated over the 7 days prior, from 0 to 10, where 0 = no symptom and 10 = worst possible symptom. Higher scores indicated more severe disease. CRCSD was analyzed using an MMRM model.","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"27"}]}],"classes":[{"title":"Appetite","categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","lowerLimit":"-0.83","upperLimit":"0.37"},{"groupId":"OG001","value":"0.20","lowerLimit":"-0.36","upperLimit":"0.76"},{"groupId":"OG002","value":"0.23","lowerLimit":"-0.37","upperLimit":"0.82"},{"groupId":"OG003","value":"0.69","lowerLimit":"0.11","upperLimit":"1.27"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","lowerLimit":"-0.82","upperLimit":"0.17"},{"groupId":"OG001","value":"0.14","lowerLimit":"-0.32","upperLimit":"0.61"},{"groupId":"OG002","value":"0.06","lowerLimit":"-0.43","upperLimit":"0.55"},{"groupId":"OG003","value":"-0.50","lowerLimit":"-0.98","upperLimit":"-0.02"}]}]},{"title":"Physical Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","lowerLimit":"-0.85","upperLimit":"0.32"},{"groupId":"OG001","value":"0.39","lowerLimit":"-0.16","upperLimit":"0.94"},{"groupId":"OG002","value":"0.38","lowerLimit":"-0.21","upperLimit":"0.96"},{"groupId":"OG003","value":"-0.06","lowerLimit":"-0.63","upperLimit":"0.51"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Appetite: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.1912","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.43","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.38","ciUpperLimit":"1.24"},{"groupIds":["OG000","OG002"],"groupDescription":"Appetite: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.1866","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.46","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.39","ciUpperLimit":"1.30"},{"groupIds":["OG000","OG003"],"groupDescription":"Appetite: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0349","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.92","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.09","ciUpperLimit":"1.75"},{"groupIds":["OG000","OG001"],"groupDescription":"Nausea: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.8754","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.47","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.20","ciUpperLimit":"1.14"},{"groupIds":["OG000","OG002"],"groupDescription":"Nausea: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.8205","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.38","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.31","ciUpperLimit":"1.08"},{"groupIds":["OG000","OG003"],"groupDescription":"Nausea: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.3375","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"-0.17","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.86","ciUpperLimit":"0.51"},{"groupIds":["OG000","OG001"],"groupDescription":"Physical Fatigue: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.9138","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.66","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.14","ciUpperLimit":"1.45"},{"groupIds":["OG000","OG002"],"groupDescription":"Physical Fatigue: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.9011","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.64","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.18","ciUpperLimit":"1.46"},{"groupIds":["OG000","OG003"],"groupDescription":"Physical Fatigue: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","nonInferiorityType":"SUPERIORITY","pValue":"=0.6618","statisticalMethod":"MMRM analysis; 1-sided","paramType":"Difference in LS Mean","paramValue":"0.21","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.61","ciUpperLimit":"1.02"}]},{"type":"SECONDARY","title":"Part A: Median Change From Baseline in CRCSD Scores at Week 12: Vomiting Frequency","description":"The CRCSD is a daily, self-reported questionnaire that measured severity of symptoms related to cancer cachexia: vomiting frequency. Participants rated vomiting frequency over the past 24 hours, from 0 to 30, where 0 = no symptom and 30 = worst possible symptom. Higher scores indicated more severe disease.","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG001","value":"0.00","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG002","value":"0.00","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG003","value":"0.00","lowerLimit":"0.0","upperLimit":"0.0"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With Treatment Emergent Adverse Events (TEAE)","description":"An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. TEAE were defined as any event that was not present before exposure to study drug, or any event already present that worsened in either intensity or frequency after exposure to study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included serious AEs and all non-SAEs.","populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From start of study drug on Day 1 maximum up to 4 weeks post last dose on Week 12 (maximum up to approximately Week 16)","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"50"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"37"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With Incidence of Laboratory Test Abnormalities","description":"Laboratory test abnormality parameters included: hematology- hemoglobin (gram per deciliter \\[g/dL\\]), hematocrit (%), erythrocytes (10\\^12/Liter \\[L\\]) less than (\\<) 0.8\\*lower limit of normal (LLN); platelets (10\\^9/L) \\<0.5\\*LLN to more than (\\>) 1.75\\*upper limit of normal (ULN); leukocytes (10\\^9/L) \\<0.6\\*LLN to \\>1.5\\*ULN; lymphocytes, neutrophils (10\\^9/L) \\<0.8\\*LLN to \\>1.2\\*ULN. Clinical chemistry- bilirubin, glucose (mg/dL) \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase (Units/L \\[U/L\\]) \\>3.0\\*ULN; protein, albumin (gram \\[g\\]/dL) \\<0.8\\*LLN; urea (mmol/L) \\>1.3xULN; creatinine (mg/dL) \\>1.3\\*ULN; sodium (milliequivalents \\[mEq\\]/L) \\<0.95\\*LLN; potassium (mEq/L) \\<0.9\\*LLN to \\>1.1\\*ULN.","populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Here, ''Overall Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 up to Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"28"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With Post-Baseline Vital Signs Meeting the Predefined Criteria","description":"Vital signs criteria included: supine systolic blood pressure (SBP) \\<90 millimeters of mercury (mmHg), increase and decrease in change of more than or equal to (\\>=) 30mmHg; supine diastolic blood pressure (DBP) \\<50 mmHg, increase and decrease in change of \\>= 20mmHg; pulse rate \\<40 beats per minute (bpm) to \\>120 bpm. Only rows which included at least 1 participant in any reporting group with abnormality were reported in this outcome measure.","populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Here, ''Overall Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 up to Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"44"}]}],"classes":[{"title":"Supine SBP Value < 90mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Supine SBP Increase Change >= 30mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}]}]},{"title":"Supine SBP Decrease Change >= 30mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"}]}]},{"title":"Supine DBP Value < 50mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Supine SBP Increase Change >= 20mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}]},{"title":"Supine DBP Decrease Change >= 20mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"}]}]},{"title":"Supine Pulse Rate Value > 120mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With Clinically Significant Echocardiogram (ECG) Abnormalities","description":"ECG parameters included heart rate (HR), PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF) and QRS complex. HR: RR (interval between 2 successive R waves on ECG) decrease \\>25% and to a VR (interval between QRS wave and T wave on ECG) \\>100, RR increase \\>25% and to a VR \\<50; PR interval: baseline less than or equal to (\\<=) 200 and % change \\>= 50%; QT interval: \\>450, \\>480, \\>500, increase from baseline \\>30, increase from baseline \\>60; QTcF: 470 \\< value \\<= 480, 480 \\< value \\<= 500, value \\> 500, 30 \\< change \\<= 60 and change \\>60; QRS complex: value \\>= 140, % change \\>=50%. Clinically significant values were determined by the investigator.","populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 up to Week 12","groups":[{"id":"OG000","title":"Part A: Placebo","description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG001","title":"Part A: Ponsegromab 100 mg","description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG002","title":"Part A: Ponsegromab 200 mg","description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses)."},{"id":"OG003","title":"Part A: Ponsegromab 400 mg","description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"50"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Part A: From start of study drug on Day 1 maximum up to 4 weeks post last dose on Week 12 (maximum up to approximately Week 16)","description":"Same event may appear as AE and SAE. What is presented are distinct events. Event may be categorized serious in 1 participant and non-serious in another, or participant may have experienced serious and non-serious event. Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. At this milestone (primary completion date) Part A safety analysis was final. Part B safety data will be reported at study completion date.","eventGroups":[{"id":"EG000","title":"Part A: Placebo","description":"Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","deathsNumAffected":5,"deathsNumAtRisk":45,"seriousNumAffected":11,"seriousNumAtRisk":45,"otherNumAffected":25,"otherNumAtRisk":45},{"id":"EG001","title":"Part A: Ponsegromab 100 mg","description":"Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","deathsNumAffected":6,"deathsNumAtRisk":46,"seriousNumAffected":15,"seriousNumAtRisk":46,"otherNumAffected":19,"otherNumAtRisk":46},{"id":"EG002","title":"Part A: Ponsegromab 200 mg","description":"Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","deathsNumAffected":6,"deathsNumAtRisk":46,"seriousNumAffected":10,"seriousNumAtRisk":46,"otherNumAffected":19,"otherNumAtRisk":46},{"id":"EG003","title":"Part A: Ponsegromab 400 mg","description":"Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","deathsNumAffected":9,"deathsNumAtRisk":50,"seriousNumAffected":20,"seriousNumAtRisk":50,"otherNumAffected":24,"otherNumAtRisk":50}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Anal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Gastrointestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Rectal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":2,"numAtRisk":50}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Intestinal fistula infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Pelvic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":2,"numAtRisk":46},{"groupId":"EG003","numAffected":3,"numAtRisk":50}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Anastomotic complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":3,"numAtRisk":46},{"groupId":"EG003","numAffected":3,"numAtRisk":50}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":46},{"groupId":"EG002","numAffected":2,"numAtRisk":46},{"groupId":"EG003","numAffected":2,"numAtRisk":50}]},{"term":"Ovarian neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Cerebral amyloid angiopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Diplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Metabolic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":45},{"groupId":"EG001","numAffected":4,"numAtRisk":46},{"groupId":"EG002","numAffected":4,"numAtRisk":46},{"groupId":"EG003","numAffected":4,"numAtRisk":50}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":45},{"groupId":"EG001","numAffected":3,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":3,"numAtRisk":50}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":45},{"groupId":"EG001","numAffected":3,"numAtRisk":46},{"groupId":"EG002","numAffected":2,"numAtRisk":46},{"groupId":"EG003","numAffected":3,"numAtRisk":50}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":45},{"groupId":"EG001","numAffected":3,"numAtRisk":46},{"groupId":"EG002","numAffected":4,"numAtRisk":46},{"groupId":"EG003","numAffected":5,"numAtRisk":50}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":4,"numAtRisk":50}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":46},{"groupId":"EG002","numAffected":2,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":3,"numAtRisk":46},{"groupId":"EG003","numAffected":4,"numAtRisk":50}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":4,"numAtRisk":50}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":4,"numAtRisk":50}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":5,"numAtRisk":46},{"groupId":"EG003","numAffected":4,"numAtRisk":50}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":2,"numAtRisk":50}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":2,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":3,"numAtRisk":50}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":0,"numAtRisk":50}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":4,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":2,"numAtRisk":50}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":45},{"groupId":"EG001","numAffected":3,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":45},{"groupId":"EG001","numAffected":6,"numAtRisk":46},{"groupId":"EG002","numAffected":0,"numAtRisk":46},{"groupId":"EG003","numAffected":6,"numAtRisk":50}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":3,"numAtRisk":46},{"groupId":"EG003","numAffected":1,"numAtRisk":50}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":46},{"groupId":"EG002","numAffected":1,"numAtRisk":46},{"groupId":"EG003","numAffected":3,"numAtRisk":50}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-06-02","uploadDate":"2025-03-11T14:38","filename":"Prot_000.pdf","size":3588608},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-04-07","uploadDate":"2025-03-11T14:38","filename":"SAP_001.pdf","size":6045974}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Czechia"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-03-27","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D010190","term":"Pancreatic Neoplasms"},{"id":"D015179","term":"Colorectal Neoplasms"},{"id":"D000855","term":"Anorexia"},{"id":"D005221","term":"Fatigue"},{"id":"D002100","term":"Cachexia"},{"id":"D009369","term":"Neoplasms"},{"id":"D015431","term":"Weight Loss"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D007414","term":"Intestinal Neoplasms"},{"id":"D005770","term":"Gastrointestinal Neoplasms"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D003108","term":"Colonic Diseases"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D012002","term":"Rectal Diseases"},{"id":"D012817","term":"Signs and Symptoms, Digestive"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D001836","term":"Body Weight Changes"},{"id":"D001835","term":"Body Weight"},{"id":"D013851","term":"Thinness"}]}},"hasResults":true}